NCT06916520View on ClinicalTrials.gov

Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2027

Conditions
Coronary Arterial Disease (CAD)Percutaneous Coronary Intervention (PCI)
Interventions
DRUG

Prasugrel 5 mg

Prasugrel 5 mg once daily (monotherapy)

DRUG

Dual Antiplatelet (DAPT) Therapy

Dual antiplatelet therapy according to guidelines

All Listed Sponsors
lead

J.P.S Henriques

OTHER